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Abstract
Disrupted in schizophrenia 1 (DISC1), a genetic risk factor for multiple serious psychiatric
diseases including schizophrenia, bipolar disorder and autism, is a key regulator of multiple
neuronal functions linked to both normal development and disease processes. As these diseases are
thought to share a common deficit in synaptic function and architecture, we have analyzed the role
of DISC1 using an approach that focuses on understanding the protein– protein interactions of
DISC1 specifically at synapses. We identify the Traf2 and Nck-interacting kinase (TNIK), an
emerging risk factor itself for disease, as a key synaptic partner for DISC1, and provide evidence
that the DISC1–TNIK interaction regulates synaptic composition and activity by stabilizing the
levels of key postsynaptic density proteins. Understanding the novel DISC1–TNIK interaction is
likely to provide insights into the etiology and underlying synaptic deficits found in major
psychiatric diseases.
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Introduction
Schizophrenia, mood disorders and autism are severe debilitating psychiatric disorders with
accumulating convergent evidence implicating dysfunction at the glutamatergic synapse.1–3
Multiple genetic studies of schizophrenia and autism have highlighted genes whose products
are found at synapses.4 Post-mortem studies show altered expression of glutamate receptors
in brains of patients with schizophrenia, major depression and bipolar disorder when
compared with healthy individuals.5,6 Likewise, the expression of PSD-95, a major scaffold
protein at the postsynaptic density (PSD) of glutamate synapses, was decreased in the
prefrontal cortex of schizophrenic brains.7 Furthermore, molecular profiling using
microarray and proteomic analyses on schizophrenia and bipolar brains have revealed
altered expression of other synaptic proteins, suggesting that synaptic deficits are associated
with these disorders.8,9
Disrupted in schizophrenia 1 (DISC1) has emerged as a strong candidate gene for
schizophrenia and other psychiatric disorders.10,11 It was originally identified through study
of a Scottish pedigree in which a balanced translocation between chromosomes 1 and 11 co-
segregates with schizophrenia, bipolar disorder and recurrent major depression.12 The name
DISC1 was given to the gene disrupted at the breakpoint on chromosome 1.13,14 Follow-up
studies have reinforced the genetic association between variation in DISC1 and major
mental illness, have highlighted links to brain structure and function10,15 and have shown
convergent genetic and biochemical links to other risk factors such as PDE4B
(phosphodiesterase 4B).16,17 In parallel with genetics, a rich biology for DISC1 function has
begun to emerge,10,11,18 with DISC1 implicated in cellular signaling, neuronal migration,
axonal transport and neurogenesis in both the developing and adult brain.19–22 The
complexity of the biology is highlighted by DISC1 being found in multiple subcellular
locations and to bind to multiple protein partners.10,11 The underlying molecular explanation
for such diversity could be the neurodevelopmentally regulated expression or post-
translational modification of different DISC1 isoforms, which could generate distinct protein
complexes and/or target to distinct subcellular locations.10 For example, DISC1 interacts
with PDE4B in mitochondria and likely synapses to regulate cyclic adenosine
monophosphate signaling,16,23 with Ndel1 at the centrosome to regulate neuronal
migration19,23 and with glycogen synthase kinase 3β to modulate Wnt signaling in neural
progenitors.21 Together, these studies suggest that DISC1 is a multifunctional scaffold likely
under exquisite spatial and temporal control, involved in different signaling pathways and of
great importance for neuronal development and function.
We became very interested in understanding the role of DISC1 at the synapse after early
reports localizing it to the PSD in human and rat brains as shown by electron microscopy
and cellular fractionation techniques, respectively.24,25 These observations were in line with
our own predictions of a synaptic role for DISC1, which arose from in silico analysis of the
‘DISC1 interactome’, a DISC1 protein–protein interaction network based on yeast two-
hybrid screening.26,27 Our approach to study DISC1 function at the synapse was through the
interrogation of DISC1-interacting proteins already known to be present in synapses. Within
this effort we selected the Traf2 and Nck-interacting kinase (TNIK), a serine/ threonine
kinase from the Ste20 kinase family, for further study, as it was shown to bind DISC1, and
had been found at the PSD in large-scale proteomic studies.28,29 In recombinant systems,
TNIK has been shown to regulate the actin cytoskeleton and c-Jun N-terminal kinase
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pathway30,31 and, recently, was found to be an essential activator of Wnt target genes in the
mouse small intestine.32 The function of TNIK in the brain is poorly understood, but its
potential importance in psychiatry has been highlighted by four independent studies
implicating TNIK in either schizophrenia or bipolar disorder.33–36 TNIK mRNA was shown
to be upregulated in the dorsolateral prefrontal cortex of schizophrenia patients33 and in
lymphoblastoid cell lines from bipolar disorder patients when compared with their healthy
monozygotic twins.34 In addition, two single-nucleotide polymorphisms in TNIK were
found to be associated with schizophrenia using functional neuroimaging as a quantitative
phenotype in the context of a genome-wide association study.35 Within the recent wave of
genome-wide association study reports, a single-nucleotide polymorphism in TNIK was in
the top 12 hits associated with schizophrenia in the African-American sample analysis from
the MGS (Molecular Genetics of Schizophrenia) consortium.36 These reports support a role
for TNIK as a susceptibility gene for schizophrenia and related diseases, and, in conjunction
with our DISC1–TNIK interaction finding, suggested a functional role of TNIK and the
DISC1–TNIK interaction in the brain.
In this study we show the importance of DISC1 and TNIK function in the regulation of key
postsynaptic proteins, including glutamate receptors, PSD-95 and stargazin, with subsequent
impact on synaptic activity. We demonstrate that TNIK is specifically expressed in neurons
where it is highly enriched in the PSD, its expression profile mirrors that of DISC1 and
DISC1 and TNIK interact in the brain. Using a combination of recombinant and neuronal
cell models we show that DISC1 inhibits TNIK kinase activity. In primary neurons, we were
able to modulate TNIK activity using both a peptide that inhibits TNIK kinase activity,
derived from its binding site on DISC1, and small hairpin RNA (shRNA)-mediated
knockdown to show that decreases in TNIK activity result in specific degradation of key
postsynaptic molecules and changes in neuronal activity. Intriguingly, knockdown of DISC1
generates a predictable contrasting profile for the same postsynaptic proteins. These results
identify TNIK as an important regulatory kinase at the PSD, which in turn is regulated by a
physical interaction with DISC1. Understanding the importance of this protein interaction in




The following primary antibodies were used in these experiments: monoclonal mouse-anti-
TNIK (BD Bio-sciences, San Jose, CA, USA); rabbit anti-TNIK-N, pTNIKS764 and
pTNIKS769 (Abgent, San Diego, CA, USA); and rabbit-anti-TNIK (Santa Cruz
Biotechnology, Santa Cruz, CA, USA). Rabbit anti-DISC1 440 (DISC1–440) was generated
in-house using antigenic peptide, H-[C]RTPHPEEEKSPLQVLQEWD-OH, which is
identical in human, mouse and rat. DISC1–440 consistently recognizes four major isoforms
from rat brain lysates, including two bands at 130kD and two around 100 kD. Anti-
hemagglutinin (HA), Myc and green fluorescent protein (Santa Cruz); anti-synaptophysin
(BD); anti-β-actin (Sigma-Aldrich); anti-PSD95 (Sigma or Cell Signaling, Danvers, MA,
USA); anti-GluR1, GluR2/3 and stargazin (Millipore, Billerica, MA, USA); anti-NR2b
(Santa Cruz); and anti-β-tubulin (Covance, Princeton, NJ, USA) were also used.
Secondary antibodies for western blot were Cruz Marker-compatible horseradish
peroxidase-conjugated antibodies (Santa Cruz). Fluorescent secondary antibodies for
immunofluorescence staining were Alexa Fluor 488 or 594 conjugated (Invitrogen,
Carlsbad, CA, USA).
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Cell line and primary neuronal cultures
HEK293 and NIH3T3 cells were maintained in Dulbecco’s modified Eagle’s medium
(Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum (Invitrogen).
Rat hippocampal and cortical neuronal cultures were prepared from 18-day-old embryonic
rats as previously described.37 Briefly, hippocampi or cortices were dissociated by enzyme
digestion with Papain Dissociation System (Worthington Biochemical, Lakewood, NJ,
USA). Hippocampal cells were plated at 750 000 cells per dish and cortical cells at 2 000
000 cells per dish on poly-D-lysine-coated 60mm dishes (BD). For imaging, hippocampal
cells were plated as 30 000 cells per coverslip on poly-D-lysine/laminin-coated 12mm
coverslips (BD). All cells were plated and maintained in Neurobasal media (Invitrogen)
supplemented with B27 and L-glutamine (Invitrogen) for 16–26 days in vitro (DIV). Half
media was replaced with fresh growth media to feed cells every week till use.
Plasmid construction and transfection
Plasmids for the expression of HA-TNIK-WT, K54R (KM), ΔKD, CNH and ΔCNH, and
EGFP-TNIK, and the expression of Myc-DISC1-WT and HA-DISC1-WT, 1–835, 1–801, 1–
748, 1–726, 1–697, 1–597, 46–854, 150–854, 245–854, 291–854, 348–854 and 403–854
were described previously.19,31,38 Plasmids for the expression of HA-DISC1–302–854,
313–854, 324–854 and 335–854 were generated by PCR-based subclon-ing. Plasmids for
the expression of Myc-DISC1-ΔTNIK and AS1–6 were generated by site-directed
mutagenesis using the Phusion Site-Directed Mutagenesis Kit (New England Biolabs,
Ipswich, MA, USA). The constructs mentioned above are all human TNIK or DISC1.
Mouse TNIK complementary DNA was cloned by reverse transcriptase-PCR from total
mouse brain mRNA and subcloned into pCDNA3.1. The knockdown-resistant construct
were generated by site-directed mutagenesis (see below for the knockdown target sequence).
All oligonucleotides for PCR were synthesized by Invitrogen Custom Primers service. All
restriction enzymes were from New England Biolabs.
For transfection of HEK293 and NIH3T3 cells, cells were seeded at 40–80% density and
transfected 24 h later using Lipofectamine 2000 (Invitrogen). For primary neuronal culture
transfection, hippocampal or cortical culture were plated at densities described above and
transfected on 7–10 DIV with a Calcium Phosphate transfection kit or Lipofectamine
(Invitrogen).
Peptides
The Tat membrane transduction domain peptide was from GenScript (Piscataway, NJ,
USA). DISCpep-WT-tat, DISCpep-PM-tat and mouse/rat DISCpep-WT-tat were
synthesized and purified by Alpha Diagnostic (San Antonio, TX, USA). All peptides were
ordered in as lyophilized powders and dissolved in distilled water at a stock concentration of
1mM. Unless specified elsewhere, 10 µM is the working concentration of peptides used in in
vitro kinase assays and primary neuronal cultures. DISCpep-WT-tat was used in in vitro
kinase assays, and mouse/rat DISCpep-WT-tat was used in rat primary neuronal cultures.
Both assays use Tat and DISCpep-PM–tat as controls (see Figure 4a for sequences).
Knockdown lentiviruses and lentivirus transduction
The vector used to generate shRNA plasmids was pLenti6-v5-D-TOPO (Invitrogen). TNIK
knockdown lentiviruses were packaged by the Mission lentivirus packaging service
provided by Sigma. The two specific target sequences for mouse and rat TNIK knockdown
were: 5′-GAAGAACAAGCTCCGTGTGTA −3′ (known as 806), and 5′-
TGGATGGAGTGTTTATG CATA-3′ (known as 807 and TNIK RNA interference
(RNAi)). In the knockdown-resistant mouse TNIK construct, the target sequences were
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changed to: 5′-AAAAAACAAACTAAGAGTATA-3′ (806), and 5′-T
GGACGGTGTATTCATGCAC-3′ (807). The amino acid residues encoded by wild-type
(WT) or mutated nucleotide sequences remained the same. Here, 801 is the empty vector
control (also known as ctrl RNAi). Primary hippocampal neurons were transduced with
knockdown lentiviruses on 7 DIV and harvested on 21 DIV when TNIK knockdown was
>50%.
DISC1 knockdown lentiviruses were described previously.19,39 The target sequence for
mouse and rat DISC1 was: 5′-GGCAAACACTGTGAAGTGC −3′ and the corresponding
scramble control was 5′-GGAGCAGACGCTGAATTAC-3′.
In situ hybridization
Autoradiographic in situ hybridization was conducted with 35S-labeled oligonucleotide
antisense probes. Briefly, radioactive oligonucleotide probes specific for TNIK (mouse
antisense: 5′-CTTGAAGAC CACCCTGACTATATTTCTGTGTGTTACC-3′; rat anti-
sense: 5′-CTTGAAGACCACCCTCACTGTATTTCTGT GTGTTACC-3′) or exon 2 of
Disc1 (mouse antisense: 5′-TATGCCATCCATGGGCATCGGCCCAGCCGCCGCC
CTGGTC-3′) were hybridized to 20 µm sections and, after washing, slides were opposed to
film for 14 days. Sense probes were tested in a similar manner and showed no signal.
Similar patterns of expression were observed in mouse tissue with additional antisense
probes corresponding to nucleotides 224-183, 940-901, 1119-1091 and 1238-1201 of TNIK
(XM_001473602.1) and to 161-121 of DISC1 (exon 2 of NM_174854).
Immunofluorescence staining of brain slices
C57/BL6 male mice (8 weeks old) were deeply anesthetized and intracardially perfused with
saline solution followed by 4% of paraformaldehyde. Brains were removed, post fixed
overnight and cryoprotected in 30% sucrose. Free-floating sections were cut at 40 µm in a
freezing microtome and kept at 20 °C in cryoprotective solution (30% sucrose, 30%
ethylenglycol and 1% polyvinylpyrrolidone in phosphate-buffered saline (PBS)) until
processing.
Sections were washed in PBS and incubated for 2 h in blocking solution (2% normal horse
serum, 0.5% bovine serum albumin and 0.5% Triton X-100 in PBS) followed by incubation
in blocking solution containing the primary antibodies: rabbit anti-TNIK (Abgent), goat
anti-DISC1 (Santa Cruz) and mouse anti-NeuN (Millipore), all 1:500 for 72 h at 4 °C. After
rinsing in PBS, sections were incubated in blocking solution containing secondary
antibodies (anti-rabbit-Rhodamine Red X, anti-goat-fluorescein and anti-mouse-Cy5) for 2h
at room temperature, and then rinsed in PBS and mounted in slides. Sections were visualized
using a Nikon confocal microscope.
Immunofluorescence staining of primary neuronal cultures
Cells on 12-mm poly-D-lysine/laminin-coated cover-slips (BD) were washed with cold PBS
and fixed with 4% paraformaldehyde in PBS for 10 min, followed by three washes with PBS
and permeabilized with 0.2% Triton X-100 in PBS for 5 min. The coverslips were then
blocked by the blocking buffer (5% normal donkey serum, 0.1% Tween 20 and PBS),
followed by incubation with primary antibodies overnight in the blocking buffer. The
coverslips were washed three times with 0.1% Tween 20 in PBS, 10 min each, followed by
incubation with fluorescent secondary antibodies in the blocking buffer for 1 h. The cover-
slips were washed three times with 0.1% Tween 20 in PBS, 10 min each, and then mounted
to glass slides (VWR) with Prolong Gold antifade reagent with 4,6-diamidino-2-
phenylindole (Invitrogen). The coverslips were observed using Leica (Wetzlar, Germany)
TCS SP5 confocal microscope ( × 63, oil).
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For surface glutamate receptor 1 (GluR1) staining, cells were fixed in 4%
paraformaldehyde/4% sucrose in PBS for 5 min and stained without permeabilization.
Electron microscopy
All procedures relating to the care and treatment of animals were in accordance with the
institutional and National Institutes of Health guidelines. Pentobarbital-anesthetized
(60mgkg−1 intraperitoneal) male Sprague-Dawley rats (3–5 months old, Charles River,
Raleigh, NC, USA) were intracardially perfused with heparinized saline followed by 500 ml
of fixative. Rats were fixed with 4% paraformaldehyde freshly depolymerized in phosphate
buffer (0.1 M, pH 6.8) for light microscopy, or with a mixture of 4% paraformaldehyde and
1% glutaraldehyde in phosphate buffer for electron microscopy. Brains were postfixed
overnight at 4 °C in the same fixative, cut at 40–50 µm on a Vibratome and collected in cold
phosphate buffer.
For pre-embedding electron microscopy, the basic procedure was identical except that
sections fixed with glutaraldehyde were first treated with sodium borohydride (1% in PBS)
to quench free aldehyde groups. After incubation with biotinylated secondary antibody,
sections were incubated for 30 min with streptavidin Nanogold (1:100 dilution), rinsed in
0.2% sodium acetate and then silver intensified by 7-min incubation in IntenSE M reagents
(GE Healthcare, Piscataway, NJ, USA) and rinsed again in sodium acetate. Reacted sections
were postfixed 45 min in 1% osmium tetroxide in phosphate buffer; after rinse in 0.1 M
maleate buffer (pH 6.0), sections were incubated for 1h in 1% uranyl acetate, then
dehydrated through graded ethanol solutions, infiltrated with Spurr’s resin, and heat-
polymerized at 60 °C. Relevant chips from cortex and hippocampus were glued onto plastic
blocks; thin sections (~80 nm) were collected on copper mesh grids and post-stained with
uranyl acetate and Sato’s lead. Control sections were processed in parallel in the absence of
primary or secondary antibodies.
Image analysis
All confocal images were captured using identical acquisition parameters, defined as those
that yielded optimal signal without saturation in control neurons. For measurements of
surface GluR1 or PSD-95 immunoreactive puncta, confocal images were analyzed using
Metamorph software (Molecular Devices, Downington, PA, USA). Only neurons exhibiting
extensive dendritic spine formation were selected for analysis. For measuring punctate area
and density, fluorescent images were thresholded such that pixels with grey values >120
(surface GluR1) and 130 (PSD-95) were binarized. For each neuron, regions of interest of
50 µm length and 4 µm width were drawn around three dendritic segments arising from the
soma and analyzed using the Metamorph Integrated Morphometry Analysis tool. For
average fluorescence intensity measurements, the same regions of interest detailed above
were analyzed using the Metamorph Region Measurements tool without thresholding. All
image analysis was performed blind of treatment conditions.
Immunoprecipitation
For preparation of cell extracts, HEK293 cells grown in six-well plates were washed once
with ice-cold PBS. Cells were then lysed in 120–150 µl of co-immunoprecipitation (co-IP)
buffer (50 mM Tris-Cl (pH 7.5), 150 mM NaCl, 1mM EDTA and 1% Triton X-100) with
freshly add protease and phosphotase inhibitor cocktails (Sigma). After rocking for 30 min
at 4 °C, cell lysates were collected by scraping and cleared by centrifugation at 12000 g for
10min at 4 °C.
For preparation of tissue extracts, freshly dissected rat brain tissues were cut to small pieces
and immediately put into ice-cold co-IP buffer with protease and phosphotase inhibitors,
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followed by brief sonication. The tissue lysates were then rocked at 4 °C for 30 min and
cleared by centrifugation at 12 000 g for 10 min at 4 °C. Another 5 min of centrifugation at
12 000 g was performed if lysates were still cloudy.
A total of 20 µl of protein G-Sepharose 4 beads (GE Healthcare) equilibrated with co-IP
buffer were mixed with 1–3 µg of antibodies. After 1 h of incubation, the beads were
washed one time with co-IP buffer, then mixed with cell or tissue lysates, and incubated 2 h
to overnight at 4 °C with rocking. The beads were washed extensively with co-IP buffer to
remove unbound proteins, separated by NuPage 4–12% Bis-Tris gels (Invitrogen) and
subjected to western blotting.
Crude membrane fractionation
Primary hippocampal neurons were homogenized in homogenization buffer (320 mM
sucrose, 50 mM Tris-Cl (pH 7.5) and 1mM EDTA) by passing through 26-gauge needles for
10 times, followed by centrifugation at 1000 g for 5 min. The supernatant was then spun at
45 000 r.p.m. for 1 h. The supernatant and pellet are cytosol and crude membrane fractions,
respectively.
Synaptosome and PSD fractionation of rat brain
The fractionation was performed as previously described.24 Briefly, rat hippocampi or
cortices were homogenized with a Teflon-glass homogenizer, followed by 1400 g
centrifugation for 10 min to remove nuclei and unbroken cells and the supernatant was S1
and pellet P1. The S1 was centrifuged at 13 130 g for 10 min to yield S2 and crude
synaptosomal pellet P2, which was further fractionated by discontinuous sucrose gradient
centrifugation at 82 500 g for 2 h to yield ER-golgi membranes and synaptosomes. To
prepare PSD fractions, the synaptosome fraction was extracted with Triton X-100, followed
by centrifugation at 33 000 g for 20 min to yield supernatant TxS1 and pellet PSD1. The
PSD1 was further extracted with Triton X-100 or Sarcosyl followed by centrifugation at 200
000 g for 20 min to yield supernatants TxP2 and SarS, and pellets PSD2 and PSD3.
Full-length human TNIK purification
Suspension-adapted HEK293-EBNA cells in 1l of freestyle 293 medium (Invitrogen) with
5% fetal bovine serum at 37 °C were transfected with 1mg of TNIK-FLAG plasmid. At 18 h
after transfection, the culture was transferred to a 31 °C incubator and allowed to incubate
for additional 72 h. Cells were harvested by centrifugation at 900 g for 5 min.
In all, 0.5l of cells were lysed in 150 ml 50 mM Tris pH 7.5, 100 mM NaCl, 50 mM NaF,
5% glycerol, 5 mM β-glycerophosphate, 1 mM Na orthovanadate, Complete protease
inhibitor tablets EDTA-free (Roche, Indianapolis, IN, USA) and 6mg per 100 ml AEBSF (4-
(2-aminoethy1)benzenesulfonyl fluoride hydrochloride; Sigma). The lysate was cleared by
centrifugation and the soluble protein was batch bound with 1ml of FLAG resin (Sigma)
rotating at 4 °C for 3.5 h. The FLAG resin was washed with 10 ml tris-buffered saline.
TNIK was then batch eluted with 5 ml of elution buffer (tris-buffered saline, 0.1mg/ml−1
FLAG peptide (Sigma) and then run over a Superdex 200 size exclusion column (GE) in
tris-buffered saline, 5% glycerol and 5 mM dithiothreitol. The elution fractions were pooled
and frozen at −80 °C with 40% glycerol.
In vitro kinase assays
Purified human TNIK was incubated with indicated peptides for 30 min on ice and the
kinase reaction was carried out at 30 °C for 40 min in kinase buffer (50 mM Tris-Cl (pH
7.5), 5 mM MgCl2, 5 mM MnCl2, 5 mM dithiothreitol and 0.01% Triton X-100) with 5 µM
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adenosine triphosphate (ATP), 5 µCi [γ-32p]-ATP and 2 µg of myelin basic protein (MBP)
as substrate in a 16 ml reaction volume.
For IP kinase assays, TNIK was semi-purified from rat brain or cultured cells by IP as
previously described. The protein G beads were extensively washed with co-IP buffer
containing 700 mM NaCl and then equilibrated in the kinase buffer. The kinase reactions
were carried out with 5 µM ATP, 5 µCi [γ-32p]-ATP and 2 µg of MBP as substrate in 40 µl
reaction volume with 20 µl of protein G beads.
Electrophysiology recordings
For DISC1 peptide treatment, miniature excitatory postsynaptic currents (mEPSCs) in
cultured hippocampal neurons were recorded. Patch electrodes (3–5 MO) were filled with
the following internal solution (in mM unless specified): 130 Cs-methane-sulfate, 10 CsCl, 4
NaCl, 1 MgCl2, 5 EGTA, 10 HEPES, 5 MgATP, 0.5 Na2GTP, 12 phosphocreatine, 20
leupeptin, 1 QX314, pH 7.2–7.3, 265–270 mosml−1. The external solution consisted of (in
mM unless specified): 127 NaCl, 5 KCl, 2 MgCl2, 2 CaCl2, 12 glucose, 10 HEPES, 0.5 µM
TTX, pH 7.4, 300 mosm/l−1. Bicuculline (10 µM) was added to the external solution to
block GABAA receptors and AP-5 (50 µM) was added to block N-methyl D-aspartate
receptors. Recordings were obtained with an Axon Instruments 200B patch clamp amplifier
that was controlled and monitored with an IBM PC running pCLAMP with a DigiData 1320
series interface (Axon instruments, Foster City, CA, USA). Electrode resistances were
typically 2–4 MΩ in the bath. After seal rupture, series resistance (4– 10 MΩ) was
periodically monitored. The cell membrane potential was held at −70 mV. The Mini
Analysis Program (Synaptosoft, Leonia, NJ, USA) was used to analyze synaptic activity.
For each different condition, mEPSC recordings of 8 min were used for analysis. Statistical
comparisons of the amplitude and frequency of mEPSCs (mean ± s.e.m.) were made using
the Student’s t-test.
For TNIK knockdown, mEPSCs were recorded in cultured rat hippocampal neurons (DIV
14–18) after transfection with control or TNIK knockdown shRNA constructs (ctrl RNAi
and TNIK RNAi, respectively). In order to test whether the decrease in mEPSC amplitude
could be restored, hippocampal neurons were co-transfected with TNIK RNAi and a TNIK
construct resistant to knockdown (TNIKResistant) or wild-type TNIK construct (TNIKWT).
Statistical comparisons of the amplitude and frequency of mEPSCs (mean ± s.e.m.) were
made using the Student’s t-test.
Statistics
Unless specified elsewhere, Student’s t-test was used to determine the statistical significance
between two groups. MS Excel 2003 or GraphPad Prism 5 was used for data analysis and
graph generation. Statistical significance was indicated by *P<0.05, **P<0.01 and
***P<0.001. Error bar indicates s.e.m.
Results
A 13-amino acid region on DISC1 is required for its interaction with TNIK
Previously, DISC1 and TNIK were reported to interact in a yeast two-hybrid screen, but the
interaction was never confirmed in other systems.26 In this study we show that HA-tagged
TNIK and myc-tagged DISC1 are co-precipitated in a complex after coexpression in
HEK293 cells (Figures 1a and b). Deletion of the kinase domain of TNIK (HA-TNIK ΔKD)
abolished the interaction. However, kinase activity is not required for the interaction, as the
kinase-dead mutant30 (HA-TNIK K54R) retained the ability to interact with DISC1 (Figures
1a and b). Through similar co-IP assays with truncated N- and C-terminal DISC1 fragments,
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the binding site for TNIK was mapped to a 13-amino acid region, which extended from
residue 335 to residue 347 on DISC1 (Supplementary Figure 1). Deletion of residues 329–
350, as in the Myc-DISC1 ΔTNIK construct, led to the abolition of interaction with TNIK,
which is consistent with the location of the binding site within the 335–347 region of TNIK
(Figures 1c and d). Furthermore, alanine substitution (AS) mutants indicated that a three-
amino-acid stretch (V336, L337 and R338) together with N344 on DISC1 are crucial for the
interaction. DISC1 containing the mutation VLR336–338AAA (Myc-DISC1 AS1) only
showed a weak interaction with TNIK, comparable to DISC1 ΔTNIK (Figures 1c and d).
Identification of this binding site enabled us to generate tools to dissect out a role for the
DISC1– TNIK interaction (see below).
DISC1 associates with TNIK in the brain
TNIK protein is abundant in the brain and absent from most peripheral tissues in rats.40
However, its specific localization and function in the brain are poorly characterized.
Therefore, we utilized in situ hybridization, immunohistochemistry, immunofluorescence,
electron microscopy and biochemical fractionation to determine the localization of TNIK in
the brain and its relationship to the distribution of DISC1 (Figures 2a–e, Supplementary
Figures 2a–d). The in situ hybridization showed that TNIK mRNA is expressed throughout
the mouse brain, but appears to be particularly high in the dentate gyrus of hippocampus and
the cerebellum, with significant levels in the cortex, very similar to the pattern shown for
DISC1 (Figure 2a). TNIK mRNA was also observed in similar regions of rat brain
(Supplementary Figure 2a). The hippocampus and cortex are critical anatomical substrates
in schizophrenia, and hence we focused our subsequent experiments on these regions.
Immunohistochemistry of mouse brain sections showed colocalization of DISC1 and TNIK
in projections in the CA1 of hippocampus (Figure 2b) and the somatosensory cortex
(Supplementary Figure 2b). Immunofluorescence labeling of primary hippocampal cultures
showed that TNIK colocalizes with the neuronal marker MAP2 (microtubule-associated
protein 2), but not with the glial marker, glial fibrillary acidic protein, indicating that TNIK
is specifically expressed in neurons (Figure 2c). More specifically, the punctate staining of
TNIK colocalized extensively with the puncta of PSD-95 and the AMPA receptor subunit
GluR1, suggesting that TNIK is found at excitatory synapses (Figure 2c). Critically, TNIK
also colocalized with DISC1 dendritic puncta in primary hippocampal neurons (Figure 2c).
Electron microscopy provided further evidence that TNIK is present in dendritic spines and
localized both to pre- and postsynaptic compartments, with enrichment in the latter (Figure
2d). This pattern is very similar to that observed for DISC1 (Figure 2d).
The postsynaptic localization of TNIK was confirmed biochemically after fractionation of
rat hippocampi, which showed TNIK to be greatly enriched in PSD fractions, alongside
DISC1 (Figure 2e and Supplementary Figure 2d). Most importantly, endogenous TNIK and
DISC1 specifically co-immunoprecipitate from rat brain, utilizing either a DISC1 (Figure 2f,
left) or TNIK (Figure 2f, right) antibody to isolate the complex. Together, colocalization and
co-IP of endogenous TNIK and DISC1 proteins provide convincing evidence that DISC1
interacts with TNIK in the brain and implicate the PSD as a major functional site for these
complexes.
DISC1 inhibits the kinase activity of TNIK in cells
To determine whether DISC1 regulates TNIK kinase activity, we utilized a cell rounding
assay, which was previously shown to be dependent on TNIK kinase activity.30 Expression
of TNIK in Phoenix-A, NIH3T3 and Hela cells results in the disruption of F-actin structure
and inhibition of cell spreading.30 This was shown to be dependent on the kinase activity, as
a kinase-dead mutant, TNIK K54R, did not cause this effect.30 NIH3T3 cells were
transfected with TNIK WT or TNIK K54R alone. As expected, expression of TNIK WT
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induced cell rounding, whereas cells expressing TNIK K54R exhibited a regular
morphology comparable to neighboring non-transfected cells (Figure 3a and Supplementary
Figures 3a and b). Expression of DISC1 WT alone did not alter cell spreading or
morphology, with DISC1 exhibiting a strong punctate staining in the cytoplasm and weak
staining in the nucleus, consistent with previous observations41 (Figure 3a and
Supplementary Figure 3a). Remarkably, when TNIK was co-transfected with DISC1, it was
unable to induce cell rounding (Figure 3b and Supplementary Figure 3a). Furthermore,
TNIK was found to be colocalized with DISC1 at cytoplasmic puncta (Figure 3b and
Supplementary Figure 3a).
To further determine the specificity of the inhibition, TNIK was co-transfected with either
empty vector or DISC1 WT. We also tested DISC1 ΔTNIK, or DISC1 AS1, whose
interaction with TNIK was abolished by these mutations (Figures 1c and d). As TNIK
staining overlaps with F-actin cytoplasmic staining in NIH3T3 cells, it can be objectively
used to reflect the morphology of a cell (Supplementary Figure 3 and Supplementary Figure
4). Therefore, the length-to-breadth ratio of a cell, as determined from TNIK staining, was
used as a surrogate measure of cell rounding (Figures 3c and d and Supplementary Figure
4). Consistent with the protein–protein interaction results, DISC1 WT significantly
increased the average length-to-breadth ratio of a cell, compared with the empty vector
control and the two non-binding mutants, DISC1 ΔTNIK and DISC1 AS1, when co-
expressed with TNIK (Figures 3c and d). These results indicate that the interaction of DISC1
with TNIK is required for the inhibition of TNIK kinase activity. As DISC1 binds to the
kinase domain of TNIK, we suggest that DISC1 may directly inhibit kinase activity, but
cannot rule out an effect through regulating the subcellular localization of TNIK.
The binding site-derived DISC1 peptide inhibits TNIK kinase activity
To study the function of the TNIK–DISC1 interaction in neurons, we synthesized a 21-mer
peptide conjugated to the membrane transduction domain of Tat, whose sequence reflected
the region of DISC1 that contains the residues critical for the interaction with TNIK (Figures
1c and d and Supplementary Figure 1). We hypothesized that this 32-mer peptide, known as
DISCpep-WT-tat, would enter cells so as to disrupt specifically the interaction of DISC1
and TNIK and/or inhibit the kinase activity of TNIK. As controls, we also synthesized the
11-mer Tat membrane transduction domain peptide and a related 32-mer tat-conjugated
peptide known as DISCpep-PM-tat (point mutation) where the sequence is mutated to
VLR336–338AAA (AS1) that does not interact with TNIK (Figure 1c and Figure 4a).
We hypothesized that the DISCpep-WT-tat peptide might ablate the interaction between
DISC1 and TNIK in vitro. However the DISCpep-WT-tat peptide or the tat control peptide
was unable to disrupt the DISC1 and TNIK interaction, as shown by co-IP from HEK293
cells or from rat brain. We attempted to competitively disrupt the interaction by performing
the co-IP in the presence of peptides (Supplementary Figure 5). We conclude that the
interaction between DISC1 and TNIK cannot be disrupted by DISCpep-WT-tat peptide,
because it is of such high affinity, because the conformation of the peptide is such that it
cannot mimic a surface able to interact with DISC1, or because of additional binding sites.
As DISC1 inhibits the kinase activity of TNIK in cells, we wondered whether the DISCpep-
WT-tat peptide might behave similarly as the whole DISC1 protein, as this would provide a
means of both evaluating whether this peptide interacted with TNIK and whether this region
contributed to the observed inhibitory effect that DISC1 exerts on TNIK activity. These
peptides were tested in an in vitro TNIK kinase assay using MBP as substrate
(Supplementary Figure 6a) and purified human TNIK. DISCpep-WT-tat strongly inhibited
the kinase activity of TNIK, compared with reactions without peptide or with Tat control
peptide (Figures 4b and c). The DISCpep-PM-tat peptide only showed marginal inhibition of
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MBP phosphorylation compared with Tat, suggesting that the three mutated amino acid
residues are crucial for efficient inhibition of TNIK (Figures 4b and c). This result is
consistent with the data that DISC1 AS1 could not inhibit TNIK in cell-based assays
(Figures 3c and d). Similar to many other kinases, autopho-sphorylation enhances the kinase
activity of TNIK (Supplementary Figure 6b). To determine if the DISCpep-WT-tat peptide
is also able to inhibit TNIK in its autophosphorylated state, kinase assays were performed
with TNIK after a pre-autophosphorylation step. DISCpep-WT-tat showed an inhibition
profile similar to that observed with the non-auto phosphorylated form of TNIK (Figures 4b
and c). To determine if DISCpep-WT-tat also inhibits TNIK in complex with its interactors,
endogenous TNIK was immunoprecipitated, under mild conditions that preserve binding to
a range of interacting partners (Q Wang and NJ Brandon, unpublished), from HEK293 cells
or 22DIV rat hippocampal cultures, followed by a kinase assay using MBP as substrate
(Figures 4d and e). DISCpep-WT-tat strongly inhibits the kinase activity of endogenous
TNIK as well as purified TNIK (Figure 4). It is worth noting that TNIK from neuronal
cultures is much more active than TNIK from HEK293 cells, although more TNIK was
immunoprecipitated from HEK293 cells. This suggests that the kinase activity of TNIK is
dependent on the cellular environment from which it is isolated.
These data, together with the cell rounding assay, provide strong evidence that DISC1 is a
negative regulator of TNIK kinase activity. Importantly, we have developed a DISC1
sequence-based peptide tool that inhibits TNIK kinase activity and will allow further
analysis of TNIK activity in neurons.
The inhibitory DISC1 peptide leads to dephosphorylation of TNIK and reduction in TNIK
protein level
The rat version of peptide DISCpep-WT-tat was introduced into rat primary hippocampal
cultures as a specific inhibitor of TNIK, using Tat and DISCpep-PM-tat as control peptides
(Figure 4a). Unfortunately, endogenous substrate(s) of TNIK are currently unknown, thus
precluding the direct assessment of TNIK kinase activity. In addition, although TNIK
contains multiple phosphorylation sites throughout its 1360 amino acids (data not shown),
the identity of possible residues that might act as markers of kinase activity are unknown as
well. We therefore used two commercially available TNIK phospho-antibodies against
pSer764 and pSer769, which are phosphorylation sites identified by proteomic studies of the
human kinome.42,43 The specificity of these two antibodies was confirmed by western blot
analysis of lysates expressing TNIK or TNIK AS mutants at these residues (Supplementary
Figure 7a). Although phosphorylation of either serine is not required for MBP
phosphorylation in vitro (Supplementary Figures 7b and c), glutamate receptor agonists and
kinase activators actively regulate the phosphorylation of these two sites (Supplementary
Figure 7d). Treatment of cells with DISCpep-WT-tat caused a marked decrease (about 50%)
in the phosphorylation of TNIK at residues Ser764 and Ser769 (Figure 5a). To our surprise,
however, such treatment also caused a marked reduction in total TNIK protein level
(decreased by ~50% within 40min treatment of DISCpep-WT-tat). In contrast, the control
DISCpep-PM-tat peptide only showed a marginal decrease in the phosphorylation of
Ser769, but had no effect on the total TNIK level and phosphorylation of Ser764 (Figure
5a).
In parallel, filamentous-to-globular-actin ratio was increased with DISCpep-WT-tat
treatment (Figure 5b). This effect is likely because of inhibition of TNIK, as overexpression
of TNIK in HEK293 cells has been shown to induce actin depolymerization and decrease
the filamentous-to-globular-actin ratio.30 DISCpep-WT-tat also induced the rapid
translocation of TNIK and actin from cytosolic to membrane fractions within 10 min of
DISCpep-WT-tat treatment (Supplementary Figure 8). Importantly, control peptides had
marginal or no activity on such effects (Figure 5b, Supplementary Figure 8).
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Together, these data suggest that the DISCpep-WT-tat peptide specifically inhibits TNIK in
primary hippocampal cultures likely by regulating both the absolute level of TNIK protein
and its intrinsic kinase activity.
Inhibition of TNIK leads to specific decreases of key PSD proteins
We have previously shown that TNIK and DISC1 are localized and enriched at the PSD
(Figures 2c–e). In addition, the total protein level and phosphorylation of TNIK are actively
regulated in primary hippocam-pal cultures after treatment with glutamate receptor agonists
or kinase-activating drugs (Supplementary Figure 7d). Together, these data suggested that
TNIK might have a crucial role in signal transduction events during neuronal activation at
the synapse, leading us to examine the consequence of TNIK inhibition by DISCpep-WT-tat
on key synaptic proteins. Strikingly, within 40 min of treatment with DISCpep-WT-tat, the
total protein levels of the AMPA receptor subunit GluR1, the transmembrane AMPA
receptor regulatory protein stargazin, and the PSD scaffold protein PSD-95 were all
dramatically decreased (Figure 5c). Interestingly, the dynamic interaction of these three
molecules is important for the trafficking and function of AMPA receptors at the
synapse.44–47 Other AMPA receptor subunits (GluR2/3), the N-methyl D-aspartate receptor
subunit NR2B and the presynaptic protein synaptophysin were not changed with the peptide
treatment over the 40 min time range (Figure 5c). In addition, this specific effect of the
DISCpep-WT-tat peptide was dose dependent and consistent between both primary
hippocampal and cortical cultures (Supplementary Figure 9).
To understand the time course of the protein loss with the DISCpep-WT-tat peptide, we
measured protein levels after 5, 10, 20 and 40 min of treatment. Dephosphorylation of TNIK
and decreases in PSD-95 were observed at 5 min, suggesting that TNIK inhibition induces a
rapid signaling cascade leading to protein degradation (Supplementary Figure 10).
Furthermore, over the 40-min time course, there was good separation in the effects of
DISCpep-WT-tat from the control peptide DISCpep-PM-tat, on inducing decreases in
TNIK, GluR1, PSD-95 and stargazin (Supplementary Figure 10). Together, these results
suggest that TNIK activity is required to maintain the level of key synaptic proteins, with
inhibition of TNIK resulting in a rapid depletion of these proteins.
Inhibition of TNIK induces degradation of PSD proteins
The reduction in GluR1 and PSD-95 protein levels occurs within minutes of DISCpep-WT
treatment, leading us to hypothesize that inhibition of TNIK in this manner might selectively
increase protein degradation rates. To test this hypothesis, primary hippo-campal cultures
were treated with the proteasome inhibitor MG132, or the lysosome inhibitor leupeptin,
before treatment with Tat peptides. The reduction in TNIK protein levels induced by
DISCpep-WT-tat was rescued by MG132 but not leupeptin. However, dephosphorylation of
TNIK at S764 was not affected by MG132, and S769 was neither affected by MG132 or
leupeptin treatments (Figures 6a and b). This suggests that DISCpep-WT-tat still alters
TNIK phosphorylation status in the presence of MG132 or leupeptin. Critically, the loss of
PSD-95 protein was blocked by MG132, but not leupeptin, with a reciprocal effect observed
for GluR1 (Figures 6a and b). The degradative pathways implied from these data are
consistent with the cytoplasmic protein PSD-95 being degraded through the proteasome, and
the transmembrane receptor GluR1 through the lysosome.48,49 These results suggest that
TNIK is a critical signaling molecule at the synapse that protects specific postsynaptic
proteins, such as PSD-95 and GluR1, from degradation.
Inhibition of TNIK leads to decreases in surface GluR1 and AMPA receptor currents
To determine whether the observed degradation of PSD proteins occurred at synapses,
immunofluorescence staining was performed on hippocampal neurons after 30 min of
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treatment with the various Tat peptides. Treatment with DISCpep-WT-tat specifically
decreased both the size and total intensity of surface GluR1 and PSD-95 immunoreactive
puncta per 50 µm of dendrite in comparison to both DISCpep-PM and tat alone (Figures 7a
and b and Supplementary Figure 11). The puncta density of surface GluR1 along dendrites
was also decreased in comparison to both control peptides, whereas there was a more
modest effect on PSD95 puncta density with significance over DISCpep-PM but not tat.
Consistent with these imaging data, we were able to record decreases in amplitude and
frequency of isolated AMPA receptor mEPSCs in primary hippocampal neurons after
treatment with DISCpep-WT-tat (Figure 7c). Together, these results suggest that not only
does inhibition of TNIK lead to reductions in the total protein levels of GluR1 and PSD95,
but it also reduces their level at the synapse and reduces synaptic strength.
DISC1 and TNIK regulate AMPA receptors in a reciprocal but complex manner
The DISCpep-WT-tat peptide experiments suggest that TNIK has an important role in the
life cycle of a number of PSD proteins. To gain additional data to support these
observations, we developed lentiviral-expressed shRNA reagents to knock down TNIK
expression levels. We characterized two independent shRNA constructs (shRNAs 806 and
807) directed against distinct sequences of TNIK, which reduced expression levels of
overexpressed mouse/rat TNIK in HEK293 cells (Supplementary Figure 12a). Moreover,
both shRNAs effectively knocked down endogenous TNIK levels in primary hippocampal
cultures 14 days after virus transduction (Supplementary Figures 12b and c). We used the
more potent virus shRNA-807 in all further experiments, together with the control empty
virus 801 (named TNIK RNAi and ctrl RNAi) to demonstrate the effects of knocking down
TNIK levels. Thus, we evaluated the effects of TNIK knockdown on the same set of PSD
proteins as analyzed above for the peptide experiments. Intriguingly, and in contrast to the
peptide experiments, all PSD proteins tested, including GluR1, GluR2/3, NR2B, PSD-95
and stargazin, were reduced by TNIK knockdown, whereas the presynaptic protein synap-
tophysin was unchanged (Figures 8a and b). Such differences could be because of the
different approaches taken (kinase inhibition versus protein depletion) or because of the time
course of the experiments (chronic knockdown versus acute kinase inhibition). TNIK
knockdown also resulted in reduced surface levels of GluR1 as measured by pulldown of
biotinylated surface proteins (Figures 8c and d). Consistent with this, the amplitude of
isolated AMPA receptor mEPSCs was decreased with TNIK knockdown. Critically, this
decrease could be rescued by co-transfection of a knockdown-resistant TNIK construct, but
not by wild-type TNIK (Figure 8e and Supplementary Figure 12a). The effects of TNIK
knockdown support the suggested role of TNIK in the maintenance of PSD protein stability.
As DISC1 binds TNIK in the PSD and is an inhibitor of TNIK kinase activity, we set out to
evaluate the effect of DISC1 knockdown on the pool of proteins regulated by TNIK activity.
We hypothesized that depletion of DISC1 should lead to an elevation in TNIK activity and
hence a phenotype reciprocal to that observed with either TNIK knockdown or use of the
DISC1 inhibitory peptide, DISCpep-WT-tat. Indeed, DISC1 knockdown, using a well-
characterized shRNA lentivirus,19,39 caused an increase in GluR1 and GluR2/3 (Figure 8f).
DISC1 knockdown also led to an increase in the level of TNIK protein, suggesting that not
only does DISC1 regulate the activity of TNIK but also its degradation (Figure 8f). DISC1
knockdown also reduced levels of PSD-95 and stargazin (Figure 8f). These latter effects
may be explained by the effects of DISC1 depletion on other DISC1 interactors and
functions.11,26 Together, these data indicate that the DISC1–TNIK interaction regulates
glutamate receptors and other critical PSD proteins in a dynamic fashion.
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Changes in the molecular composition and signaling properties of the PSD serve as an
important mechanism to alter synaptic strength, which is thought to underlie information
storage and learning-related plasticity,50,51 whereas deficits in synaptic form and function
are now considered primary molecular insults that lead to a range of psychiatric and
neurological disorders. This study identifies the DISC1–TNIK complex, a combination of
two emerging disease risk factors, as a new molecular player at excitatory synapses. We
demonstrate for the first time that TNIK maintains levels of glutamate receptors and other
key PSD proteins at the synapse, with loss of TNIK protein or inhibition of TNIK activity
causing rapid degradation of PSD constituents. DISC1 appears to be a key cellular brake for
TNIK activity as (1) in a cellular overexpression system, DISC1 inhibits TNIK activity in a
manner that is dependent on DISC1 binding to TNIK (Figure 3) and (2) a peptide derived
from the TNIK binding site on DISC1 (DISCpep-WT-tat) inhibits TNIK kinase activity and
leads to the degradation of postsynaptic proteins in hippocampal neurons (Figure 4–Figure
6). In addition, this treatment also resulted in a loss of AMPAR GluR1 surface staining at
synapses and a reduction in AMPAR mEPSCs (Figure 7). Together, these data suggest that
regulation of TNIK activity either directly, or indirectly through DISC1, can modulate
synaptic strength. Intriguingly, inhibition of TNIK with the peptide DISCpep-WT also led to
a reduction in total protein levels of TNIK that could account for some of the effects we see
on postsynaptic proteins, as mimicked by the shRNA experiments. It is critical to note that
in primary cultures treated with MG132 and subsequent DISCpep-WT-tat, GluR1
degradation still occurred, although the total protein loss of TNIK was rescued by MG132
(Figures 6a and b), suggesting that the kinase activity of TNIK, probably regulated by
phosphorylation, is required for the maintenance of some PSD proteins.
The importance of TNIK in regulating components of the PSD was reinforced by knocking
down TNIK using shRNAs. We again saw a decrease in a range of PSD proteins,
accompanied by decreases in GluR1 surface expression and AMPAR currents (Figure 8).
Intriguingly, when we knocked down DISC1, we saw a partially reciprocal set of protein
changes as seen with TNIK knockdown. We observed predicted increases in the levels of
TNIK and GluR1 but surprisingly a very large decrease in PSD-95 levels. This latter
finding, which did not fit our hypothesis, might be explained by effects of DISC1 loss on
other PSD-localized DISC1 complexes.26 In particular, the interaction between kalirin-7 and
DISC1 may be relevant for this effect. Indeed, in a separate study we have recently shown
that DISC1 binds to kal-7 and PSD-95 in a tri-molecular signalosome, to prevent access of
kal-7 to rac1 and regulate spine size.39 It is possible that depletion of DISC1 from the kal-7
pool may destabilize PSD-95 and mask possible increases resulting from a disinhibition of
TNIK. Consequently, it is now vital to understand the function of the DISC1–TNIK
interaction at the synapse within the context of other DISC1-interacting proteins, in
particular kal-7. Knowledge of the downstream signaling pathways from TNIK and kal-7
identifies convergence at the level of regulation of the actin cytoskeleton.52 It is now critical
to understand whether these effects are independent or possibly components of a single
linear pathway. Intriguingly, we show that TNIK is regulated by N-methyl D-aspartate
receptor activation (Supplementary Figure 7d), which has also been shown to regulate the
complex of DISC1, kal-7 and PSD-95.39 Again, whether TNIK activity might have a role in
the formation and stabilization of this tri-p-artite complex awaits additional studies. In
addition, a number of other DISC1 partners are localized to the synapse, for example,
PDE4,53 but we believe that the effects we observe with the DISCpep-WT peptide are
specific to TNIK, as the TNIK binding site does not overlap with known binding sites of
other DISC1 interactors, including PDE4, NUDEL, Grb2, glycogen synthase kinase-33β and
Girdin,17,20,21,54–56 and the effects we are observing are likely to be through inhibition of
kinase activity rather than through disruption of protein–protein interactions. We do not yet
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understand the downstream effectors of TNIK kinase activity that are responsible for
regulating PSD protein degradation. We are currently identifying TNIK substrates, but do
not have likely candidate(s) that would explain the data reported here. Previous studies
highlighted the importance of TNIK in regulating the actin cytoskeleton,30,31 and we
speculate that actin regulatory proteins could be important targets. This possibility is
supported by our demonstration that DISC1 inhibits TNIK-induced cell rounding, an actin-
dependent process, in HEK293 cells, and that inhibiting TNIK by the DISCpep-WT-tat
peptide induces the translocation of actin from the cytosol to the membrane and increases
the filamentous-to-globular-actin ratio in primary hippocampal cultures (Figure 3 and Figure
5b and Supplementary Figure 8). It is not clear that these TNIK–actin events have a role in
TNIK regulation of PSD proteins. However, actin is highly enriched at the PSD, where it
anchors receptors and regulates receptor trafficking,57 enabling TNIK to synergistically
regulate the composition and structure of dendritic spines.
In conclusion, we show that TNIK and DISC1 are key regulators of components of the PSD
and consequently of synapse form and function. As deficits in synaptic function are
implicated in diseases like autism and schizophrenia, a deeper molecular understanding of
risk factors like DISC1 has the potential to create new opportunities for understanding and
treating these diseases.
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Refer to Web version on PubMed Central for supplementary material.
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A 13-amino acid region on DISC1 is required for its interaction with TNIK. (a) Schematic
representation of TNIK with the N-terminal kinase domain (KD) and C-terminal citron
homology domain (CNH). The point mutant K54R is a kinase-dead mutant. (b) DISC1 binds
to the kinase domain of TNIK. Myc-DISC1 co-immunoprecipitates with HA-TNIK WT but
not HA-TNIK ΔKD from HEK293 cells. (c) Schematic representation of DISC1 and point
mutants within the TNIK binding site. Amino acids 329–350 are deleted in DISC1 ΔTNIK.
DISC1 AS1–6 are alanine substitution (AS) mutants with the underlined amino acid residues
mutated to alanine. (d) Amino acids crucial for the interaction of DISC1 and TNIK. Myc-
DISC1 WT, but not myc-DISC1 DTNIK, co-immunoprecipitates with HA-TNIK from
HEK293 cells.
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DISC1 associates with TNIK in the brain. (a) Expression of TNIK and DISC1 mRNA in
adult mouse brain shown by in situ hybridization. (b) Single plane confocal images of CA1
from adult mice immunostained for DISC1 (green), TNIK (red) and the neuronal marker
NeuN (blue) showing colocalization of DISC1 and TNIK in likely dendritic projections. (c)
Single plane confocal images of 19–26 DIV rat primary hippocampal cultures showing
colocalization of TNIK with neuronal and PSD markers and DISC1, but not with the glial
marker, glial fibrillary acidic protein (GFAP). (d) Electron micrographs, with pre-
embedding immunogold staining, showing the presence of TNIK and DISC1 in adult rat
CA1 dendritic spines. (e) TNIK and DISC1 are enriched in PSD fractions from rat
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hippocampi. BH, brain homogenate; ERGO, ER and Golgi apparatus; P1, nuclei and
unbroken cells; P2, organelles; PSD1–3, PSD fractions 1–3; S1, cytoplasm; SarS, Sarcosyl
soluble fraction; TxS1 and 2, Triton X-100 soluble fractions 1 and 2. (f) Co-
immunoprecipitation of TNIK and DISC1 from rat brain. IPs were performed with
DISC1-440 (left) and TNIK Santa Cruz (Right) antibodies, followed by western blotting
(WB) using both antibodies.
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DISC1 inhibits TNIK kinase activity-dependent cellular outputs. (a) Kinase-dependent cell
rounding induced by TNIK. NIH3T3 cells were transfected with HA-TNIK WT, K54R or
Myc-DISC1 WT alone, followed by immunofluorescence staining with anti-HA or anti-Myc
antibody. (b) DISC1 inhibits TNIK-induced cell rounding. NIH3T3 cells were co-
transfected with HA-TNIK WT and Myc-DISC1 WT followed by immunofluorescence
staining with anti-HA and anti-Myc antibodies. (c) The TNIK binding site on DISC1 is
required for inhibition of TNIK-induced cell rounding. Representative images of cells with
indicated co-transfection and stained for HA-TNIK, and the length-to-breadth ration of cells
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were analyzed in (d) as a surrogate measure of cell spreading. N>30. *P<0.05, **P<0.01,
***P<0.001.
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The binding site-derived DISC1 peptide inhibits TNIK kinase activity. (a) Sequences of
DISC1 peptides fused with the membrane transduction domain of Tat. DISCpep-WT
contains amino acids 329–349 of human DISC1 and DISCpep-PM has three residues
substituted by alanine. Mouse/rat version of DISCpep-WT contains amino acids 330–350 in
mouse DISC1 and is 100% identical in mouse and rat. (b) DISCpep-WT inhibits kinase
activity of TNIK in vitro. Kinase reactions were carried out using MBP as substrate with
0.15 µM of purified human TNIK and 10 µM peptides with or without a TNIK pre-
autophosphorylation step. (c) Summary of DISC1 peptide effects. MBP phosphorylation in
each reaction was normalized to the reaction with Tat peptide but without pre-
Wang et al. Page 24













autophosphorylation (lane 2). (d) DISCpep-WT inhibits kinase activity of endogenous
TNIK. Kinase reactions were carried out using MBP as substrate with endogenous TNIK
immunoprecipitated from HEK293 cells or 22 DIV rat hippocampal cultures (top) and 10
µM of indicated peptides. The kinase input for each reaction was shown by western blotting
using an anti-TNIK antibody (middle) and MBP input by Coomassie blue staining (bottom).
(e) Summary of DISCpep-WTeffect on endogenous TNIK. MBP phosphorylation in each
reaction was normalized to the reaction with Tat peptide and TNIK from HEK293 cells.
N=3. *P<0.05, **P<0.01, ***P<0.001.
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DISC1-derived peptide inhibits TNIK and regulates levels of PSD proteins in primary
hippocampal neurons. (a) DISCpep-WT causes a reduction in total TNIK and phospho-
TNIK levels. Primary hippocampal neurons (16–22 DIV) were treated with 10 µM of
indicated peptides for 40 min. N= 3. (b) DISCpep-WT increases the filamentous-to-globular
(F/G)-actin ratio. Cultures were treated as in (a), followed by Triton X-100 extraction to
separate Triton soluble (TxS) and Triton insoluble (TxIS) fractions. TxS and TxIS contain
G- and F-actin, respectively.30 N= 3. (c) DISCpep-WT causes a reduction in total levels of
key PSD proteins. Peptide treatment was same as (a) except indicated proteins were
analyzed. N=3. Total protein was normalized to β-actin, and phosphorylated protein to
corresponding total protein. *P<0.05, **P<0.01, ***P<0.001.
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Loss of PSD95 and GluR1 after inhibition of TNIK is through proteasomal and lysosomal
degradation pathways. (a) Degradation of PSD-95 and GluR1 was rescued by the
proteasome inhibitor, MG132, and the lysosome inhibitor, leupeptin, respectively. Primary
hippocampal neurons (16–22 DIV) were pretreated with 10µM of MG132 or 25µgml−1 of
leupeptin for 7 h before treatment with 10 µM of the indicated peptide for 40min. (b)
Summary of the effects of MG132 and leupeptin. N=4. Total protein was normalized to β-
actin, and phosphorylated protein to corresponding total protein. *P < 0.05, **P<0.01,
***P<0.001.
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Inhibition of TNIK leads to decreases in both the surface levels of GluR1 and AMPAR
mEPSCs. (a) Representative images of dendritic segments of primary hippocampal neurons
(19–22 DIV) treated with 10 µM of indicated peptide for 30min, followed by
immunostaining for surface GluR1 and PSD-95. (b) DISCpep-WT treatment decreases the
size, density and intensity of the surface GluR1 and PSD-95 puncta. N= 15. (c) DISCpep-
WT treatment decreases both mEPSC amplitude and frequency of primary hippocampal
neurons (13 or 19 DIV) pretreated for 40 min with indicated peptides. Representative traces
are shown on the right. N≥4. *P<0.05, **P<0.01, ***P<0.001.
Wang et al. Page 28













Wang et al. Page 29














DISC1 and TNIK regulate components of the PSD in a complex fashion. (a, b) TNIK
knockdown by a lentiviral-expressed shRNA regulates the level of PSD proteins in primary
hippocampal cultures consistent with effects mediated by peptide inhibition. N=4. (c, d)
TNIK shRNA knockdown causes decreases in total and surface GluR1. N=5. (e) TNIK
shRNA knockdown causes decreases in mEPSC amplitude, but not frequency, in primary
hippocampal neurons, and this decrease can be rescued by knockdown-resistant TNIK but
not by WT TNIK. The representative traces are shown on the right. N≥4. (f) DISC1
knockdown regulates the level of PSD proteins in primary hippocampal cultures. N=3. Total
protein was normalized to β-actin, and phosphorylated protein to corresponding total
protein. *P<0.05, **P< 0.01, ***P<0.001.
Wang et al. Page 30
Mol Psychiatry. Author manuscript; available in PMC 2012 April 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
